This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n20http://linked.opendata.cz/resource/domain/vavai/projekt/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F12%3A33140640%21RIV13-MZ0-15110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F12%3A33140640%21RIV13-MZ0-15110___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Background/Aims: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Among the side-effects of cetuximab hypomagnesaemia has been described, but the information is still limited. Methodology: We have evaluated retrospectively serum magnesium, potassium, calcium, creatinine and albumin in 51 consecutive patients with metastatic colorectal carcinoma treated with cetuximab, mostly combined with irinotecan-based combination chemotherapy. Results: A significant decrease of serum magnesium, potassium, calcium and corrected serum calcium, creatinine and albumin concentrations was already evident one week after the start of treatment. Hypomagnesaemia of any grade was detected in 56% of evaluable patients, but grade 3 or grade 4 hypomagnesaemia was observed in 6% and 4% of patients, respectively. Grade 1 hypokalemia was detected in 47%, grade 3 in 17% and grade 4 hypokalemia was detected in 6% of the patients. Among evaluable patients grade 1 hypocalcaemia was detected in (36%), grade 2 hypocalcaemia in 42%, grade 3 in 4% and grade 4 in 13% of patients. Baseline hypocalcaemia of grade 1 or higher was associated with significantly inferior survival. Conclusions: Asymptomatic hypomagnesaemia, hypokalemia and hypocalcaemia are common in metastatic colorectal carcinoma patients treated with cetuximab. Hypocalcaemia is a predictor of poor prognosis. Background/Aims: Cetuximab is a chimeric antibody registered for the therapy of advanced colorectal carcinoma. Among the side-effects of cetuximab hypomagnesaemia has been described, but the information is still limited. Methodology: We have evaluated retrospectively serum magnesium, potassium, calcium, creatinine and albumin in 51 consecutive patients with metastatic colorectal carcinoma treated with cetuximab, mostly combined with irinotecan-based combination chemotherapy. Results: A significant decrease of serum magnesium, potassium, calcium and corrected serum calcium, creatinine and albumin concentrations was already evident one week after the start of treatment. Hypomagnesaemia of any grade was detected in 56% of evaluable patients, but grade 3 or grade 4 hypomagnesaemia was observed in 6% and 4% of patients, respectively. Grade 1 hypokalemia was detected in 47%, grade 3 in 17% and grade 4 hypokalemia was detected in 6% of the patients. Among evaluable patients grade 1 hypocalcaemia was detected in (36%), grade 2 hypocalcaemia in 42%, grade 3 in 4% and grade 4 in 13% of patients. Baseline hypocalcaemia of grade 1 or higher was associated with significantly inferior survival. Conclusions: Asymptomatic hypomagnesaemia, hypokalemia and hypocalcaemia are common in metastatic colorectal carcinoma patients treated with cetuximab. Hypocalcaemia is a predictor of poor prognosis.
dcterms:title
Hypomagnesaemia in Patients with Metastatic Colorectal Carcinoma Treated with Cetuximab Hypomagnesaemia in Patients with Metastatic Colorectal Carcinoma Treated with Cetuximab
skos:prefLabel
Hypomagnesaemia in Patients with Metastatic Colorectal Carcinoma Treated with Cetuximab Hypomagnesaemia in Patients with Metastatic Colorectal Carcinoma Treated with Cetuximab
skos:notation
RIV/61989592:15110/12:33140640!RIV13-MZ0-15110___
n17:predkladatel
n18:orjk%3A15110
n3:aktivita
n5:P n5:I
n3:aktivity
I, P(NS9690)
n3:cisloPeriodika
114
n3:dodaniDat
n6:2013
n3:domaciTvurceVysledku
n12:3986659 n12:3375641 n12:5290791
n3:druhVysledku
n19:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
140137
n3:idVysledku
RIV/61989592:15110/12:33140640
n3:jazykVysledku
n16:eng
n3:klicovaSlova
Potassium; Magnesium; Colorectal carcinoma; Cetuximab; Calcium; Albumin
n3:klicoveSlovo
n4:Albumin n4:Potassium n4:Calcium n4:Cetuximab n4:Magnesium n4:Colorectal%20carcinoma
n3:kodStatuVydavatele
DE - Spolková republika Německo
n3:kontrolniKodProRIV
[933C94D29E05]
n3:nazevZdroje
Hepato-Gastroenterology
n3:obor
n7:FD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
8
n3:projekt
n20:NS9690
n3:rokUplatneniVysledku
n6:2012
n3:svazekPeriodika
59
n3:tvurceVysledku
Kalábová, Hana Melichar, Bohuslav Hyšpler, Radomír Králíčková, Pavlína Cerman, Jaroslav Malířová, Eva Holečková, Petra Študentová, Hana
s:issn
0172-6390
s:numberOfPages
6
n13:doi
10.5754/hge10330
n11:organizacniJednotka
15110